UPDATE - LifeMD Reports Second Quarter 2026 Results
LifeMD reported Q2 revenue of $47.3 million, within guidance, while adjusted EBITDA loss improved 21% sequentially to $3.5 million on gross margin expansion to 89%. Management revised full-year 2026 revenue guidance down to $205.5 million to $212.5 million and adjusted EBITDA to a range of a $6 million loss to breakeven, lowering prior expectations due to the strategic shift to branded therapies.
Key figures
- Revenue
- 47300000
- Guidance
- FY26 revenue $205.5M-$212.5M; Adj EBITDA ($6.0M) to breakeven
- Cash
- 25100000
- Gross margin
- 89%
- Active subscribers
- 356000
- Exit run rate revenue
- 250000000
- Exit run rate adj ebitda
- 22000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.